{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:29:20Z","timestamp":1785806960055,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In de novo kidney transplant recipients (KTR) treatment with belatacept has been established as a comparable option as maintenance immunosuppression, preferably as a strategy to convert from calcineurin inhibitor (CNI)- to belatacept-based immunosuppression. Switch to belatacept demonstrated improved renal function in patients with CNI-induced nephrotoxicity, but risk of transplant rejection and the development of donor-specific antibodies (DSA) are still a matter of debate. Only few data are available in patients at increased immunological risk and late after transplantation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We analyzed 30 long-term KTR (including 2 combined pancreas-KTR) converted from CNI to belatacept &gt;\u200960\u2009months after transplantation with moderate to severe graft dysfunction (GFR\u2009\u2264\u200945\u2009mL\/min). Biopsies were classified according to the Banff 2015 criteria. Group differences were assessed in a univariate analysis using Mann Whitney U or Chi square test, respectively. Multivariate analysis of risk factors for treatment failure was performed using a binary logistic regression model including significant predictors from univariate analysis. Fifty-six KTR matched for donor and recipient characteristics were used as a control cohort remaining under CNI-treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Patient survival in belatacept cohort at 12\/24\u2009months was 96.7%\/90%, overall graft survival was 76.7 and 60.0%, while graft survival censored for death was 79.3%\/66.7%. In patients with functioning grafts, median GFR improved from 22.5\u2009mL\/min to 24.5\u2009mL\/min at 24\u2009months. Positivity for DSA at conversion was 46.7%. From univariate analysis of risk factors for graft loss, GFR\u2009&lt;\u200925\u2009mL\/min (<jats:italic>p<\/jats:italic>\u2009=\u20090.042) and Banff microvascular inflammation (MVI) sum score\u2009\u2265\u20092 (<jats:italic>p<\/jats:italic>\u2009=\u20090.023) at conversion were significant at 24\u2009months. In the analysis of risk factors for treatment failure, a MVI sum score\u2009\u2265\u20092 was significant univariately (<jats:italic>p<\/jats:italic>\u2009=\u20090.023) and in a bivariate (<jats:italic>p<\/jats:italic>\u2009=\u20090.037) logistic regression at 12\u2009months. DSA-positivity was neither associated with graft loss nor treatment failure. The control cohort had comparable graft survival outcomes at 24\u2009months, albeit without increase of mean GFR in patients with functioning grafts (\u0394GFR of \u2212\u20093.6\u2009\u00b1\u20098.5\u2009mL\/min).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Rescue therapy with conversion to belatacept is feasible in patients with worsening renal function, even many years after transplantation. The benefit in patients with MVI and severe GFR impairment remains to be investigated.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-020-01992-6","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T11:02:57Z","timestamp":1597921377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-1491","authenticated-orcid":false,"given":"Mira","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Brakemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Duerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"issue":"24","key":"1992_CR1","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","volume":"349","author":"BJ Nankivell","year":"2003","unstructured":"Nankivell BJ, Borrows RJ, Fung CL, O\u2019Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326\u201333.","journal-title":"N Engl J Med"},{"issue":"12","key":"1992_CR2","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2215\/CJN.03820609","volume":"4","author":"RS Gaston","year":"2009","unstructured":"Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol. 2009;4(12):2029\u201334.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1992_CR3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","volume":"12","author":"F Vincenti","year":"2012","unstructured":"Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012;12(1):210\u20137.","journal-title":"Am J Transplant"},{"issue":"26","key":"1992_CR4","first-page":"2600","volume":"374","author":"F Vincenti","year":"2016","unstructured":"Vincenti F. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374(26):2600\u20131.","journal-title":"N Engl J Med"},{"issue":"11","key":"1992_CR5","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","volume":"16","author":"A Durrbach","year":"2016","unstructured":"Durrbach A, Pestana JM, Florman S, Del Carmen RM, Rostaing L, Kuypers D, et al. Long-term outcomes in Belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant. 2016;16(11):3192\u2013201.","journal-title":"Am J Transplant"},{"issue":"12","key":"1992_CR6","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1111\/ajt.14452","volume":"17","author":"F Vincenti","year":"2017","unstructured":"Vincenti F, Blancho G, Durrbach A, Grannas G, Grinyo J, Meier-Kriesche HU, et al. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly. Am J Transplant. 2017;17(12):3219\u201327.","journal-title":"Am J Transplant"},{"issue":"5","key":"1992_CR7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/ajt.12721","volume":"14","author":"C Leibler","year":"2014","unstructured":"Leibler C, Matignon M, Pilon C, Montespan F, Bigot J, Lang P, et al. Kidney transplant recipients treated with belatacept exhibit increased naive and transitional B cells. Am J Transplant. 2014;14(5):1173\u201382.","journal-title":"Am J Transplant"},{"issue":"3","key":"1992_CR8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1681\/ASN.2017060679","volume":"29","author":"C Leibler","year":"2018","unstructured":"Leibler C, Thiolat A, Henique C, Samson C, Pilon C, Tamagne M, et al. Control of humoral response in renal transplantation by Belatacept depends on a direct effect on B cells and impaired T follicular helper-B cell crosstalk. J Am Soc Nephrol. 2018;29(3):1049\u201362.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1992_CR9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.ajkd.2016.09.021","volume":"69","author":"JM Grinyo","year":"2017","unstructured":"Grinyo JM, Del Carmen RM, Alberu J, Steinberg SM, Manfro RC, Nainan G, et al. Safety and efficacy outcomes 3 years after switching to Belatacept from a Calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial. Am J Kidney Dis. 2017;69(5):587\u201394.","journal-title":"Am J Kidney Dis"},{"key":"1992_CR10","doi-asserted-by":"crossref","first-page":"5)","DOI":"10.1111\/ctr.12951","volume":"31","author":"V Nair","year":"2017","unstructured":"Nair V, Liriano-Ward L, Kent R, Huprikar S, Rana M, Florman SS, et al. Early conversion to belatacept after renal transplantation. Clin Transpl. 2017;31:5).","journal-title":"Clin Transpl"},{"issue":"7","key":"1992_CR11","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/ajt.13698","volume":"16","author":"Y Le Meur","year":"2016","unstructured":"Le Meur Y, Aulagnon F, Bertrand D, Heng AE, Lavaud S, Caillard S, et al. Effect of an early switch to Belatacept among Calcineurin inhibitor-intolerant graft recipients of kidneys from extended-criteria donors. Am J Transplant. 2016;16(7):2181\u20136.","journal-title":"Am J Transplant"},{"issue":"2","key":"1992_CR12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2215\/CJN.05840710","volume":"6","author":"L Rostaing","year":"2011","unstructured":"Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen RM, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011;6(2):430\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"1992_CR13","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/tri.12822","volume":"29","author":"S Brakemeier","year":"2016","unstructured":"Brakemeier S, Kannenkeril D, Durr M, Braun T, Bachmann F, Schmidt D, et al. Experience with belatacept rescue therapy in kidney transplant recipients. Transpl Int. 2016;29(11):1184\u201395.","journal-title":"Transpl Int"},{"issue":"9","key":"1992_CR14","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/TP.0000000000002192","volume":"102","author":"A Darres","year":"2018","unstructured":"Darres A, Ulloa C, Brakemeier S, Garrouste C, Bestard O, Del Bello A, et al. Conversion to Belatacept in maintenance kidney transplant patients: a retrospective multicenter European study. Transplantation. 2018;102(9):1545\u201352.","journal-title":"Transplantation"},{"issue":"8","key":"1992_CR15","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.transproceed.2017.05.013","volume":"49","author":"M Durr","year":"2017","unstructured":"Durr M, Lachmann N, Zukunft B, Schmidt D, Budde K, Brakemeier S. Late conversion to Belatacept after kidney transplantation: outcome and prognostic factors. Transplant Proc. 2017;49(8):1747\u201356 e1741.","journal-title":"Transplant Proc"},{"key":"1992_CR16","first-page":"1968029","volume":"2018","author":"S Gupta","year":"2018","unstructured":"Gupta S, Rosales I, Wojciechowski D. Pilot analysis of late conversion to Belatacept in kidney transplant recipients for biopsy-proven chronic tacrolimus toxicity. J Transp Secur. 2018;2018:1968029.","journal-title":"J Transp Secur"},{"issue":"1","key":"1992_CR17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.14107","volume":"17","author":"A Loupy","year":"2017","unstructured":"Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017;17(1):28\u201341.","journal-title":"Am J Transplant"},{"key":"1992_CR18","first-page":"198","volume":"2000","author":"L Fritsche","year":"1933","unstructured":"Fritsche L, Schroter K, Lindemann G, Kunz R, Budde K, Neumayer HH. A web-based electronic patient record system as a means for collection of clinical data. Lect Notes Comput Sc. 1933;2000:198\u2013205.","journal-title":"Lect Notes Comput Sc"},{"issue":"11","key":"1992_CR19","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/j.1600-6143.2009.02799.x","volume":"9","author":"G Einecke","year":"2009","unstructured":"Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9(11):2520\u201331.","journal-title":"Am J Transplant"},{"issue":"2","key":"1992_CR20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","volume":"12","author":"J Sellares","year":"2012","unstructured":"Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388\u201399.","journal-title":"Am J Transplant"},{"issue":"3","key":"1992_CR21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","volume":"95","author":"MJ Everly","year":"2013","unstructured":"Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013;95(3):410\u20137.","journal-title":"Transplantation"},{"issue":"2","key":"1992_CR22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1600-6143.2012.04325.x","volume":"13","author":"H de Kort","year":"2013","unstructured":"de Kort H, Willicombe M, Brookes P, Dominy KM, Santos-Nunez E, Galliford JW, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant. 2013;13(2):485\u201392.","journal-title":"Am J Transplant"},{"issue":"1","key":"1992_CR23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ki.2015.276","volume":"89","author":"A Gupta","year":"2016","unstructured":"Gupta A, Broin PO, Bao Y, Pullman J, Kamal L, Ajaimy M, et al. Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. Kidney Int. 2016;89(1):217\u201325.","journal-title":"Kidney Int"},{"issue":"2","key":"1992_CR24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ki.2015.64","volume":"88","author":"N Kozakowski","year":"2015","unstructured":"Kozakowski N, Herkner H, Bohmig GA, Regele H, Kornauth C, Bond G, et al. The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss. Kidney Int. 2015;88(2):332\u201340.","journal-title":"Kidney Int"},{"issue":"1","key":"1992_CR25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/ndt\/gfy192","volume":"34","author":"N Kozakowski","year":"2019","unstructured":"Kozakowski N, Herkner H, Eskandary F, Eder M, Winnicki W, Klager J, et al. An integrative approach for the assessment of peritubular capillaritis extent and score in low-grade microvascular inflammation-associations with transplant glomerulopathy and graft loss. Nephrol Dial Transplant. 2019;34(1):166\u201374.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1992_CR26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-6143.2010.03364.x","volume":"11","author":"A Loupy","year":"2011","unstructured":"Loupy A, Hill GS, Suberbielle C, Charron D, Anglicheau D, Zuber J, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant. 2011;11(1):56\u201365.","journal-title":"Am J Transplant"},{"issue":"5","key":"1992_CR27","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1600-6143.2011.03931.x","volume":"12","author":"B Sis","year":"2012","unstructured":"Sis B, Jhangri GS, Riopel J, Chang J, de Freitas DG, Hidalgo L, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant. 2012;12(5):1168\u201379.","journal-title":"Am J Transplant"},{"issue":"11","key":"1992_CR28","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/ajt.14353","volume":"17","author":"AB Adams","year":"2017","unstructured":"Adams AB, Goldstein J, Garrett C, Zhang R, Patzer RE, Newell KA, et al. Belatacept combined with transient Calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am J Transplant. 2017;17(11):2922\u201336.","journal-title":"Am J Transplant"},{"issue":"3","key":"1992_CR29","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/ajt.15229","volume":"19","author":"C Leibler","year":"2019","unstructured":"Leibler C, Matignon M, Moktefi A, Samson C, Zarour A, Malard S, et al. Belatacept in renal transplant recipient with mild immunologic risk factor: a pilot prospective study (BELACOR). Am J Transplant. 2019;19(3):894\u2013906.","journal-title":"Am J Transplant"},{"issue":"11","key":"1992_CR30","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1111\/ajt.12863","volume":"14","author":"MA Mujtaba","year":"2014","unstructured":"Mujtaba MA, Sharfuddin AA, Taber T, Chen J, Phillips CL, Goble M, et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. Am J Transplant. 2014;14(11):2657\u201361.","journal-title":"Am J Transplant"},{"issue":"2","key":"1992_CR31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1600-6143.2012.04341.x","volume":"13","author":"MC Lowe","year":"2013","unstructured":"Lowe MC, Badell IR, Turner AP, Thompson PW, Leopardi FV, Strobert EA, et al. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am J Transplant. 2013;13(2):312\u20139.","journal-title":"Am J Transplant"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01992-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01992-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01992-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:36:39Z","timestamp":1629416199000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01992-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1992"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01992-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"6 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board of the ethics committee of Charit\u00e9 Universit\u00e4tsmedizin Berlin, Germany (approval number EA1\/252\/17). Written informed consent was obtained from all patients in a form accepted by the mentioned committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC received travel grants from Astellas.MD received travel grants and speakers honoraria from BMS, Novartis, Roche and Astellas.KB received research funds and\/or honoraria from Abbvie, Alexion, Astellas, Bristol-Myers Squibb, Chiesi, Fresenius, Genentech, Hexal, Novartis, Otsuka, Pfizer, Roche, Siemens, and Veloxis Pharma.SB received honoraria from Astellas, Bristol-Myers Squibb, Chiesi, Chilis, Novartis, Pfizer, and Roche.FB, KW, NL, DS, AK, KUE, PN have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"354"}}